NCT06081569 · NOT YET RECRUITING
Multimodal Deep Learning for the Diagnosis and Assessment of Alzheimer's Disease
This study is testing whether AI that analyzes videos of how people walk, talk, and make facial expressions can help diagnose Alzheimer's disease and mild cognitive impairment. It is not a drug trial — it is a diagnostic research study, with no phase designation, meaning it is exploratory work to build and test a new detection tool rather than a treatment approach.
You may qualify if
- . Participants' age is between 50 and 85 years old, male or female;
- . Participants graduated from primary school or above, with normal hearing, vision, and pronunciation, using Chinese as their mother tongue and Mandarin as their daily language；
- . The diagnosis of AD and MCI participants conform to the corresponding diagnostic criteria mentioned above;
- . The scores of MMSE are between 10 and 28, and the scores of CDR are no more than 2.
- . Patients or family members agree to sign informed consent.
You're excluded if
- . Participants suffer from neurological disorders that could cause dysfunction of the brain, such as depression, tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal cranial pressure hydrocephalus, and so forth;
- . Participants suffer from systematic diseases that could cause cognitive impairment, such as liver insufficiency, renal insufficiency, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, and so forth;
- . Participants suffer from diseases that are unable to cooperate with the examinations;
- . Participants cannot take magnetic resonance imaging;
- . Participants suffer from mental and neurodevelopmental retardation;
- . Participants refuse to sign informed consent.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2023-10-13